4.5 Article

International nonproprietary names for monoclonal antibodies: an evolving nomenclature system

期刊

MABS
卷 14, 期 1, 页码 -

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/19420862.2022.2075078

关键词

International Nonproprietary Name (INN); nomenclature scheme; safety; pharmaceuticals; biologics; biological drugs; antibodies; therapeutic antibodies; antibody-based drugs; antibody-drug conjugates

向作者/读者索取更多资源

Appropriate nomenclature is crucial for pharmaceutical substances and their development. The WHO INN Programme has revised the naming system for antibody-based drugs and introduced new stems to address the challenge of distinguishing names.
Appropriate nomenclature for all pharmaceutical substances is important for clinical development, licensing, prescribing, pharmacovigilance, and identification of counterfeits. Nonproprietary names that are unique and globally recognized for all pharmaceutical substances are assigned by the International Nonproprietary Names (INN) Programme of the World Health Organization (WHO). In 1991, the INN Programme implemented the first nomenclature scheme for monoclonal antibodies. To accompany biotechnological development, this nomenclature scheme has evolved over the years; however, since the scheme was introduced, all pharmacological substances that contained an immunoglobulin variable domain were coined with the stem -mab. To date, there are 879 INN with the stem -mab. Owing to this high number of names ending in -mab, devising new and distinguishable INN has become a challenge. The WHO INN Expert Group therefore decided to revise the system to ease this situation. The revised system was approved and adopted by the WHO at the 73(rd) INN Consultation held in October 2021, and the radical decision was made to discontinue the use of the well-known stem -mab in naming new antibody-based drugs and going forward, to replace it with four new stems: -tug, -bart, -mig, and -ment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据